Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The last earnings update was 51 days ago. More info.
Add to Portfolio Compare Print
- Nektar Therapeutics has significant price volatility in the past 3 months.
NKTR Share Price and Events
7 Day Returns
1 Year Returns
NKTR Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Nektar Therapeutics (NKTR) | -9.9% | -1.5% | -31.4% | -63.3% | 95.3% | 182.4% |
| US Pharmaceuticals | -3.3% | -6% | -2% | 7.1% | 5.1% | 14.4% |
| US Market | -0.3% | 2% | 8.5% | 7% | 37.7% | 46.8% |
1 Year Return vs Industry and Market
- NKTR underperformed the Pharmaceuticals industry which returned 7.1% over the past year.
- NKTR underperformed the Market in United States of America which returned 7% over the past year.
Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Nektar Therapeutics
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Nektar Therapeutics.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 13 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 7.5% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 6% |
| Pharmaceuticals Unlevered Beta | Simply Wall St/ S&P Global | 0.67 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.674 (1 + (1- 21%) (4.48%)) |
0.798 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.8 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 5.96%) |
7.5% |
Discounted Cash Flow Calculation for NasdaqGS:NKTR using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Nektar Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 7.5%) |
|
|---|---|---|---|
| 2019 | -493.70 | Analyst x4 | -459.26 |
| 2020 | -399.86 | Analyst x3 | -346.02 |
| 2021 | -270.00 | Analyst x2 | -217.35 |
| 2022 | 1.00 | Analyst x1 | 0.75 |
| 2023 | 375.57 | Analyst x2 | 261.63 |
| 2024 | 639.82 | Est @ 70.36% | 414.63 |
| 2025 | 960.20 | Est @ 50.07% | 578.84 |
| 2026 | 1,304.62 | Est @ 35.87% | 731.61 |
| 2027 | 1,642.88 | Est @ 25.93% | 857.04 |
| 2028 | 1,954.51 | Est @ 18.97% | 948.49 |
| Present value of next 10 years cash flows | $2,770.35 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $1,954.51 × (1 + 2.73%) ÷ (7.5% – 2.73%) |
$42,111.34 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $42,111.34 ÷ (1 + 7.5%)10 |
$20,435.97 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $2,770.35 + $20,435.97 |
$23,206.32 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $23,206.32 / 174.10 |
$133.29 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $133.29 |
| Current discount | Discount to share price of
$31.68
= -1 x ($31.68 - $133.29) / $133.29 |
76.2% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- Nektar Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Nektar Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Nektar Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Nektar Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in USD | $4.02 |
| NasdaqGS:NKTR Share Price ** | NasdaqGS (2019-04-18) in USD | $31.68 |
| United States of America Pharmaceuticals Industry PE Ratio | Median Figure of 29 Publicly-Listed Pharmaceuticals Companies | 18.42x |
| United States of America Market PE Ratio | Median Figure of 3,081 Publicly-Listed Companies | 18.18x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Nektar Therapeutics.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGS:NKTR Share Price ÷ EPS (both in USD) = 31.68 ÷ 4.02 |
7.89x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Nektar Therapeutics is good value based on earnings compared to the US Pharmaceuticals industry average.
- Nektar Therapeutics is good value based on earnings compared to the United States of America market.
Price based on expected Growth
Does
Nektar Therapeutics's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 7.89x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 13 Analysts |
-17.5%per year |
| United States of America Pharmaceuticals Industry PEG Ratio | Median Figure of 23 Publicly-Listed Pharmaceuticals Companies | 1.5x |
| United States of America Market PEG Ratio | Median Figure of 2,109 Publicly-Listed Companies | 1.56x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 7.89x ÷ -17.5% |
-0.45x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Nektar Therapeutics earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Nektar Therapeutics's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in USD | $9.90 |
| NasdaqGS:NKTR Share Price * | NasdaqGS (2019-04-18) in USD | $31.68 |
| United States of America Pharmaceuticals Industry PB Ratio | Median Figure of 181 Publicly-Listed Pharmaceuticals Companies | 3.44x |
| United States of America Market PB Ratio | Median Figure of 5,184 Publicly-Listed Companies | 1.91x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGS:NKTR Share Price ÷ Book Value per Share (both in USD) = 31.68 ÷ 9.90 |
3.2x |
* Primary Listing of Nektar Therapeutics.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Nektar Therapeutics is good value based on assets compared to the US Pharmaceuticals industry average.
Value checks
We assess Nektar Therapeutics's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check) Nektar Therapeutics has a total score of 5/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Nektar Therapeutics's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 2.7%.
Growth vs Market Checks
- Nektar Therapeutics's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.
- Nektar Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqGS:NKTR Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 13 Analysts | -17.5% |
| NasdaqGS:NKTR Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 13 Analysts | 8% |
| United States of America Pharmaceuticals Industry Earnings Growth Rate | Market Cap Weighted Average | 18.7% |
| United States of America Pharmaceuticals Industry Revenue Growth Rate | Market Cap Weighted Average | 5.1% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.4% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 13 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 1,500 | 44 | 149 | 5 |
| 2022-12-31 | 975 | 13 | -31 | 5 |
| 2021-12-31 | 472 | -321 | -371 | 8 |
| 2020-12-31 | 217 | -312 | -457 | 13 |
| 2019-12-31 | 115 | -409 | -529 | 12 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 1,193 | 718 | 681 |
| 2018-09-30 | 1,249 | 755 | 746 |
| 2018-06-30 | 1,374 | 920 | 903 |
| 2018-03-31 | 321 | -98 | -129 |
| 2017-12-31 | 308 | -80 | -97 |
| 2017-09-30 | 250 | -52 | -105 |
| 2017-06-30 | 133 | -173 | -209 |
| 2017-03-31 | 131 | -128 | -198 |
| 2016-12-31 | 165 | -117 | -154 |
| 2016-09-30 | 167 | -140 | -165 |
| 2016-06-30 | 191 | -126 | -130 |
| 2016-03-31 | 181 | -160 | -134 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 13 Analyst Estimates (S&P Global) | See Below |
All data from Nektar Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 1.98 | 3.11 | 0.94 | 4.00 |
| 2022-12-31 | -0.12 | 2.22 | -2.72 | 6.00 |
| 2021-12-31 | -2.02 | 0.50 | -4.41 | 7.00 |
| 2020-12-31 | -2.52 | -1.20 | -3.93 | 11.00 |
| 2019-12-31 | -3.00 | -2.49 | -3.28 | 11.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2018-12-31 | 4.02 |
| 2018-09-30 | 4.50 |
| 2018-06-30 | 5.58 |
| 2018-03-31 | -0.82 |
| 2017-12-31 | -0.62 |
| 2017-09-30 | -0.68 |
| 2017-06-30 | -1.41 |
| 2017-03-31 | -1.37 |
| 2016-12-31 | -1.10 |
| 2016-09-30 | -1.22 |
| 2016-06-30 | -0.97 |
| 2016-03-31 | -1.01 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Nektar Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
Future performance checks
We assess Nektar Therapeutics's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Nektar Therapeutics has a total score of 1/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Nektar Therapeutics performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Nektar Therapeutics has delivered over 20% year on year earnings growth in the past 5 years.
- Nektar Therapeutics has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
- Nektar Therapeutics has become profitable in the last year making it difficult to compare the US Pharmaceuticals industry average.
Earnings and Revenue History
All data from Nektar Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 1,193.32 | 681.31 | 81.44 | 399.54 |
| 2018-09-30 | 1,248.96 | 745.70 | 66.70 | 372.08 |
| 2018-06-30 | 1,374.13 | 902.71 | 60.04 | 334.90 |
| 2018-03-31 | 321.00 | -128.62 | 55.78 | 306.83 |
| 2017-12-31 | 307.71 | -96.69 | 52.36 | 268.46 |
| 2017-09-30 | 249.70 | -105.07 | 52.79 | 237.26 |
| 2017-06-30 | 133.10 | -209.16 | 50.99 | 223.50 |
| 2017-03-31 | 131.28 | -197.89 | 46.02 | 215.59 |
| 2016-12-31 | 165.44 | -153.52 | 44.28 | 203.80 |
| 2016-09-30 | 167.35 | -165.46 | 44.95 | 197.50 |
| 2016-06-30 | 190.97 | -130.44 | 44.24 | 188.78 |
| 2016-03-31 | 180.87 | -134.50 | 43.39 | 181.84 |
| 2015-12-31 | 230.78 | -81.18 | 46.47 | 179.59 |
| 2015-09-30 | 210.97 | -72.72 | 45.48 | 170.95 |
| 2015-06-30 | 283.89 | 6.09 | 45.07 | 161.92 |
| 2015-03-31 | 289.74 | 26.11 | 44.50 | 153.21 |
| 2014-12-31 | 200.71 | -53.92 | 44.13 | 144.53 |
| 2014-09-30 | 212.30 | -55.89 | 41.41 | 154.59 |
| 2014-06-30 | 140.34 | -143.04 | 42.92 | 164.30 |
| 2014-03-31 | 145.69 | -153.15 | 42.53 | 179.83 |
| 2013-12-31 | 148.92 | -162.01 | 43.43 | 187.11 |
| 2013-09-30 | 138.92 | -167.28 | 44.36 | 185.34 |
| 2013-06-30 | 96.42 | -194.28 | 43.79 | 175.44 |
| 2013-03-31 | 86.25 | -185.82 | 44.83 | 156.41 |
| 2012-12-31 | 81.19 | -171.86 | 44.41 | 145.88 |
| 2012-09-30 | 75.83 | -156.42 | 41.95 | 133.20 |
| 2012-06-30 | 84.48 | -136.95 | 44.23 | 130.21 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- Nektar Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
- Nektar Therapeutics used its assets more efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.
- Nektar Therapeutics has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
Past performance checks
We assess Nektar Therapeutics's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Nektar Therapeutics has a total score of 4/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Nektar Therapeutics's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Nektar Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
- Nektar Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Nektar Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 5.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Nektar Therapeutics Company Filings, last reported 3 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 1,717.58 | 246.95 | 1,335.35 |
| 2018-09-30 | 1,790.12 | 246.51 | 1,420.41 |
| 2018-06-30 | 1,860.41 | 246.08 | 1,823.81 |
| 2018-03-31 | 58.28 | 245.64 | 296.66 |
| 2017-12-31 | 87.83 | 245.21 | 296.13 |
| 2017-09-30 | 84.16 | 247.25 | 352.57 |
| 2017-06-30 | 3.39 | 248.10 | 265.55 |
| 2017-03-31 | 44.75 | 248.42 | 358.52 |
| 2016-12-31 | 88.13 | 243.46 | 389.10 |
| 2016-09-30 | -67.85 | 247.52 | 253.51 |
| 2016-06-30 | -39.25 | 248.94 | 274.85 |
| 2016-03-31 | -0.28 | 250.24 | 288.33 |
| 2015-12-31 | 6.43 | 247.53 | 308.94 |
| 2015-09-30 | 39.05 | 132.22 | 267.82 |
| 2015-06-30 | 35.10 | 133.53 | 254.66 |
| 2015-03-31 | 77.31 | 134.80 | 300.81 |
| 2014-12-31 | 36.33 | 133.65 | 237.82 |
| 2014-09-30 | 47.22 | 130.34 | 236.64 |
| 2014-06-30 | -35.36 | 131.03 | 276.44 |
| 2014-03-31 | -9.81 | 132.05 | 284.07 |
| 2013-12-31 | -89.90 | 136.59 | 237.03 |
| 2013-09-30 | -50.25 | 134.01 | 183.55 |
| 2013-06-30 | -40.55 | 134.90 | 201.89 |
| 2013-03-31 | -2.62 | 135.77 | 236.20 |
| 2012-12-31 | 47.02 | 136.61 | 277.19 |
| 2012-09-30 | 95.33 | 140.20 | 319.28 |
| 2012-06-30 | 132.28 | 230.76 | 432.87 |
- Nektar Therapeutics's level of debt (14.4%) compared to net worth is satisfactory (less than 40%).
- Nektar Therapeutics had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
- Debt is well covered by operating cash flow (290.8%, greater than 20% of total debt).
- Interest payments on debt are well covered by earnings (EBIT is 132.1x coverage).
Financial health checks
We assess Nektar Therapeutics's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Nektar Therapeutics has a total score of 6/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Nektar Therapeutics's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Nektar Therapeutics
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Nektar Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Nektar Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 13 Analyst Estimates (S&P Global) | See Below |
| United States of America Pharmaceuticals Industry Average Dividend Yield | Market Cap Weighted Average of 9 Stocks | 2.8% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2009 Stocks | 2.4% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.6% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | 0.00 | 1.00 |
| 2020-12-31 | 0.00 | 1.00 |
| 2019-12-31 | 0.00 | 1.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Nektar Therapeutics has not reported any payouts.
- Unable to verify if Nektar Therapeutics's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Nektar Therapeutics's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Nektar Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Nektar Therapeutics has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | $18,097,411 |
| AGE | 65 |
| TENURE AS CEO | 12.3 years |
CEO Bio
Mr. Howard W. Robin has been the Chief Executive Officer and the President of Prime Holdings & Investments Inc. since July 2001. Mr. Robin has been the Chief Executive Officer and President of Nektar Therapeutics since January 15, 2007. From January 2001 to June 2001, he served as Chief Operating Officer and President of Prime Holdings & Investments Inc. Mr. Robin served as Chief Executive Officer, President and a Director of Sirna Therapeutics, Inc., a biotechnology company, from July 2001 to November 2006 and from January 2001 to June 2001, served as their Chief Operating Officer, President and as a Director. Prior to Sirna Therapeutics, Inc., he served in a variety of functions during 20 years at Berlex Laboratories. From 1991 to 2001, Mr. Robin served as Corporate Vice President and General Manager of Berlex Laboratories Inc. From 1987 to 1991, he served as Vice President of Finance & Business Development and Chief Financial Officer of Berlex Laboratories Inc. From 1984 to 1987, he served as Director of Business Planning & Development at Berlex. Prior to Berlex, he served as a Senior Associate with Arthur Andersen & Company prior to joining Berlex. Mr. Robin has more than 25 years of successful biopharmaceutical experience managing clinical development and commercial operations. He serves as a Director of Acologix, Inc. He has been a Director of Nektar Therapeutics since February 14, 2007. He served as a Director of Bay Area Bioscience Association. Previously, He served as a Director of Prime Holdings & Investments from January 2001 to June 2001. He received his B.S. in Accounting & Finance from Farleigh Dickinson University in 1974.
CEO Compensation
- Howard's compensation has increased in line with Nektar Therapeutics recently becoming profitable.
- Howard's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Nektar Therapeutics management team in years:
- The tenure for the Nektar Therapeutics management team is about average.
Management Team
Howard Robin
CEO, President & Director
$18M
65
12.3 yrs
Gil Labrucherie
Senior VP & CFO
$8M
46
2.8 yrs
John Nicholson
Senior VP & COO
$8M
66
2.8 yrs
Steve Doberstein
Chief Research & Development Officer
$8M
59
9.3 yrs
Maninder Hora
Senior VP of Pharmaceutical Development & Chief Technical Operations Officer
$5M
64
8.7 yrs
Jillian Thomsen
Senior VP of Finance & Chief Accounting Officer
52
11 yrs
Jonathan Zalevsky
Chief Scientific Officer
1.4 yrs
Jennifer Ruddock
Senior Vice President of Investor Relations & Corporate Affairs
3.4 yrs
Mark Wilson
Senior VP
2.8 yrs
Dorian Hirth
Senior Vice President of Human Resources and Facilities Operations
Board of Directors Tenure
Average tenure and age of the Nektar Therapeutics board of directors in years:
- The tenure for the Nektar Therapeutics board of directors is about average.
Board of Directors
Rob Chess
Chairman of the Board
$557K
61
20 yrs
Howard Robin
CEO, President & Director
$18M
65
12.2 yrs
Roy Whitfield
Independent Lead Director
$526K
64
0.2 yrs
Lutz Lingnau
Independent Director
$525K
75
11.7 yrs
R. Greer
Independent Director
$542K
60
9.2 yrs
Jeff Ajer
Independent Director
$1M
56
1.6 yrs
Karin Eastham
Independent Director
69
0.6 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 22. Feb 19 | Sell | Stephen Doberstein | Individual | 19. Feb 19 | 19. Feb 19 | -3,310 | $42.39 | $-140,311 | ||
| 22. Feb 19 | Sell | Howard Robin | Individual | 19. Feb 19 | 19. Feb 19 | -8,882 | $42.39 | $-376,508 | ||
| 22. Feb 19 | Sell | Gil Labrucherie | Individual | 19. Feb 19 | 19. Feb 19 | -3,592 | $42.39 | $-152,265 | ||
| 22. Feb 19 | Sell | Maninder Hora | Individual | 19. Feb 19 | 19. Feb 19 | -2,386 | $42.39 | $-101,143 | ||
| 22. Feb 19 | Sell | John Nicholson | Individual | 19. Feb 19 | 19. Feb 19 | -3,822 | $42.39 | $-162,015 | ||
| 22. Feb 19 | Sell | Jillian Thomsen | Individual | 19. Feb 19 | 19. Feb 19 | -1,808 | $42.39 | $-76,641 | ||
| 19. Nov 18 | Sell | Stephen Doberstein | Individual | 16. Nov 18 | 16. Nov 18 | -4,524 | $38.25 | $-173,043 | ||
| 19. Nov 18 | Sell | Howard Robin | Individual | 16. Nov 18 | 16. Nov 18 | -15,326 | $38.25 | $-586,220 | ||
| 19. Nov 18 | Sell | Gil Labrucherie | Individual | 16. Nov 18 | 16. Nov 18 | -6,515 | $38.25 | $-249,199 | ||
| 19. Nov 18 | Sell | Maninder Hora | Individual | 16. Nov 18 | 16. Nov 18 | -4,694 | $38.25 | $-179,546 | ||
| 19. Nov 18 | Sell | Jillian Thomsen | Individual | 16. Nov 18 | 16. Nov 18 | -4,016 | $38.25 | $-153,612 | ||
| 19. Nov 18 | Sell | John Nicholson | Individual | 16. Nov 18 | 16. Nov 18 | -5,982 | $38.25 | $-228,812 | ||
| 15. Aug 18 | Sell | Dennis Winger | Individual | 13. Aug 18 | 14. Aug 18 | -34,250 | $61.04 | $-2,075,379 | ||
| 07. Jun 18 | Buy | Roy Whitfield | Individual | 05. Jun 18 | 06. Jun 18 | 5,000 | $59.80 | $290,212 | ||
| 18. May 18 | Sell | Stephen Doberstein | Individual | 16. May 18 | 16. May 18 | -3,435 | $83.39 | $-286,445 | ||
| 18. May 18 | Sell | Jillian Thomsen | Individual | 16. May 18 | 16. May 18 | -3,576 | $83.39 | $-298,203 | ||
| 18. May 18 | Sell | Howard Robin | Individual | 16. May 18 | 16. May 18 | -12,791 | $83.39 | $-1,066,641 | ||
| 18. May 18 | Sell | Gil Labrucherie | Individual | 16. May 18 | 16. May 18 | -4,941 | $83.39 | $-412,030 | ||
| 18. May 18 | Sell | Maninder Hora | Individual | 16. May 18 | 16. May 18 | -4,060 | $83.39 | $-338,563 | ||
| 18. May 18 | Sell | John Nicholson | Individual | 16. May 18 | 16. May 18 | -4,917 | $83.39 | $-410,029 | ||
Management checks
We assess Nektar Therapeutics's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Nektar Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Is Nektar Therapeutics (NASDAQ:NKTR) A High Quality Stock To Own?
Our data shows Nektar Therapeutics has a return on equity of 40% for the last year. … That means that for every $1 worth of shareholders' equity, it generated $0.40 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleIs Nektar Therapeutics (NASDAQ:NKTR) Potentially Underrated?
As an investor, I look for investments which does not compromise one fundamental factor for another. … By this I mean, I look at stocks holistically, from their financial health to their future outlook.
Simply Wall St - – Full articleNektar Therapeutics (NASDAQ:NKTR) Investors Are Paying Above The Intrinsic Value
Help shape the future of investing tools and you could win a $250 gift card! … by taking the foreast future cash flows of the company and discounting them back to today's value. … Discounted Cash Flows (DCF)
Simply Wall St - – Full articleIs Nektar Therapeutics's (NASDAQ:NKTR) CEO Paid Enough Relative To Peers?
Howard Robin has been the CEO of Nektar Therapeutics (NASDAQ:NKTR) since 2007. … This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Howard Robin's Compensation Compare With Similar Sized Companies?
Simply Wall St - – Full articleHas Nektar Therapeutics (NASDAQ:NKTR) Got Enough Cash?
This article will examine NKTR’s financial liquidity and debt levels to get an idea of whether the company can deal with cyclical downturns and maintain funds to accommodate strategic spending for future growth. … Remember this is a very top-level look that focuses exclusively on financial health, so I recommend a deeper analysis. … Check out our latest analysis for Nektar Therapeutics
Simply Wall St - – Full articleIs Nektar Therapeutics's (NASDAQ:NKTR) CEO Incentives Align With Yours?
This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Howard Robin's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that Nektar Therapeutics has a market cap of US$8.4b, and is paying total annual CEO compensation of US$18m.
Simply Wall St - – Full articleIs Nektar Therapeutics's (NASDAQ:NKTR) Liquidity Good Enough?
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Nektar Therapeutics (NASDAQ:NKTR), with a market capitalization of US$9.59b, rarely draw their attention from the investing community. … Let’s take a look at NKTR’s debt concentration and assess their financial liquidity to get an idea of their ability to fund strategic acquisitions and grow through cyclical pressures. … Note that this commentary is very high-level and solely focused on financial health, so I suggest you dig deeper yourself.
Simply Wall St - – Full articleWhen Will Nektar Therapeutics (NASDAQ:NKTR) Become Profitable?
With the latest financial year loss of -US$96.69m and a trailing-twelve month of -US$128.62m, the US$9.92b market-cap amplifies its loss by moving further away from its breakeven target? … I’ve put together a brief outline of industry analyst expectations for NKTR, its year of breakeven and its implied growth rate … According to the industry analysts covering NKTR, breakeven is near.
Simply Wall St - – Full articleAt $77.83, Is It Time To Buy Nektar Therapeutics (NASDAQ:NKTR)?
Today we're going to take a look at the well-established Nektar Therapeutics (NASDAQ:NKTR). … Let’s take a look at Nektar Therapeutics’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change. … Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations.
Simply Wall St - – Full articleNektar Therapeutics (NASDAQ:NKTR): Will The Growth Last?
Nektar Therapeutics's (NASDAQ:NKTR) most recent earnings announcement in December 2017 suggested that losses became smaller relative to the prrior year's level as a result of recent tailwinds Today I want to provide a brief commentary on how market analysts predict Nektar Therapeutics's earnings growth trajectory over the next couple of years and whether the future looks brighter. … Check out our latest analysis for Nektar Therapeutics Market analysts' prospects for the coming year seems pessimistic, with earnings becoming even more negative, arriving at -US$232.36M in 2019. … The advantage of this method is that we can get a bigger picture of the direction of Nektar Therapeutics's earnings trajectory over the long run, irrespective of near term fluctuations, be more volatile.
Simply Wall St - – Full articleCompany Info
Description
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for solid tumors; and NKTR-255, which is in preclinical stage for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; CIMZIA for crohn’s disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA and Pfizer Inc to develop a therapy for treating pancreatic cancer. Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California.
Details
| Name: | Nektar Therapeutics |
| NKTR | |
| Exchange: | NasdaqGS |
| Founded: | 1990 |
| $5,515,629,261 | |
| 174,104,459 | |
| Website: | http://www.nektar.com |
| Address: |
Nektar Therapeutics 455 Mission Bay Boulevard South, San Francisco, California, 94158, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGS | NKTR | Common Stock | Nasdaq Global Select | US | USD | 03. May 1994 | |
| DB | ITH | Common Stock | Deutsche Boerse AG | DE | EUR | 03. May 1994 | |
| LSE | 0UNL | Common Stock | London Stock Exchange | GB | USD | 03. May 1994 |
Number of employees
Current staff
Industry
| Pharmaceuticals | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/04/21 23:37 |
| End of day share price update: | 2019/04/18 00:00 |
| Last estimates confirmation: | 2019/03/21 |
| Last earnings filing: | 2019/03/01 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
